Posted by Michael Wonder on 26 Nov 2019
Mavenclad granted accelerated access by NICE
26 November 2019 - Merck has announced good news for some multiple sclerosis patients, as its Mavenclad (cladribine) has been given a National Institute for Health and Care Excellence guidance update.
The organisation’s Technology Appraisal Guidance (TAG) now states that the multiple sclerosis drug can be used as an option for treating highly active versions of the disease in adults without the requirement of a gadolinium-enhanced MRI scan.
The decision is a result of a partnership with the Accelerated Access Collaborative (AAC), which brings industry, government and the NHS together to remove barriers to uptake of innovations, so that NHS patients have faster access to innovations that can “transform care.”
